The Chemours Company (NYSE:CC) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026, reporting third-quarter net income of $196 million and nine-month net sales of $4,512 million.

Key Highlights

  • Q3 2026 net sales: $1,540 million, compared with $1,495 million in Q3 2025, according to the filing.
  • Q3 2026 net income attributable to Chemours: $196 million, or $1.29 per basic and diluted share, versus $46 million, or $0.31 per share, in Q3 2025.
  • Nine-month net loss attributable to Chemours: $(107) million, or $(0.71) per basic and diluted share, for the nine months ended September 30, 2026.
  • PFAS Insurance MOU: SG&A expense for the three and nine months ended September 30, 2026 includes $150 million received by the company related to a PFAS Insurance MOU, per the filing.
  • Total assets: $7,293 million as of September 30, 2026, compared with $7,382 million at December 31, 2025.
  • Long-term debt, net: $3,783 million as of September 30, 2026, down from $4,099 million at December 31, 2025.
  • Shares outstanding: 150,534,489 shares of common stock outstanding as of November 2, 2026.

Chemours Financial Results for the Quarter and Nine Months Ended September 30, 2026

According to the filing, Chemours reported net sales of $1,540 million for the three months ended September 30, 2026, compared with $1,495 million for the same period in 2025. Gross profit for Q3 2026 was $231 million, slightly below $233 million in Q3 2025. Net income attributable to Chemours for the third quarter was $196 million, or $1.29 per basic and diluted share, a significant increase from $46 million, or $0.31 per share, in Q3 2025.

A notable item affecting the period, per the filing, is that selling, general, and administrative expense for both the three and nine months ended September 30, 2026 includes $150 million received by the company related to the PFAS Insurance MOU. The filing directs readers to Note 17, Commitments and Contingent Liabilities, for further details. For the nine months ended September 30, 2026, the company reported a net loss attributable to Chemours of $(107) million, or $(0.71) per share, compared with a net loss of $(339) million, or $(2.26) per share, for the same period in 2025. The nine-month period also included a loss on extinguishment of debt of $(11) million and other income, net of $347 million, according to the filing.

On the balance sheet, the filing reported total assets of $7,293 million as of September 30, 2026. Long-term environmental remediation liabilities increased to $689 million from $530 million at December 31, 2025. Total Chemours stockholders' equity stood at $155 million, compared with $250 million at year-end 2025. Cash and cash equivalents were $698 million at September 30, 2026, up from $670 million at December 31, 2025. Long-term debt, net, declined to $3,783 million from $4,099 million at December 31, 2025.

What Was Disclosed

Chemours filed its quarterly report for the period ended September 30, 2026, disclosing Q3 net income of $196 million, a $150 million PFAS Insurance MOU receipt affecting SG&A, reduced long-term debt, and a nine-month net loss of $(107) million, with 150,534,489 shares outstanding as of November 2, 2026.